Combined inhibition of the vitamin d receptor and poly(adp) ribose polymerase (parp) in the treatment of cancer
AssigneeInstitute for Cancer Research d/b/a The Research Institute of Fox Chase Cancer Center
InventorsTimothy J. Yen, Vikram Bhattacharjee
Life of this patent
Estimating the term…
Abstract
Methods for treating tumors comprise contacting tumor cells expressing the vitamin D receptor with a vitamin D receptor ligand that inhibits homologous recombination in the tumor cells, and contacting the tumor cells with an amount of a Poly(ADP) Ribose Polymerase 1 (PARP-1) inhibitor. Inhibiting homologous recombination produces a synergistic therapeutic effect between the vitamin D receptor ligand and PARP-1 inhibitor, and may overcome PARP-1 resistance in killing tumor cells.
Claims20
A method for killing tumor cells expressing the vitamin D receptor, comprising contacting the tumor cells with a vitamin D receptor ligand in an amount effective to inhibit homologous recombination in the tumor cells, and contacting the tumor cells with a therapeutically effective amount of a Poly(ADP) Ribose Polymerase 1 (PARP-1) inhibitor, wherein the combination of the vitamin D receptor ligand and the PARP-1 inhibitor exhibits therapeutic synergy in killing the tumor cells.
Dependencies are inferred from the claim text.